Evotec SE (EVO) Interest Expenses (2009 - 2026)
Evotec SE (EVO) reported Interest Expenses of -$118.25 for Q1 2026, up 88.83% on a YoY basis from -$62.62 in Q1 2025, and up 89.27% sequentially from -$1102.4 in Q3 2025.
Evotec SE (EVO) Interest Expenses (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 10 years of Interest Expenses data on file, last reported at -$118.25 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 88.83% year-over-year to -$118.25; the trailing twelve-month figure through Mar 2026 stood at -$4264.5 (up 32.38% YoY), and the FY2022 full-year result was $13.4 million, up 19.34% from the prior year.
- Interest Expenses improved to -$118.25 in Q1 2026, from -$1102.4 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $13.4 million in Q4 2022 to a low of -$4657.7 in Q1 2022.
- A 5-year average of $1.1 million and a median of -$1080.3 in 2025 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses jumped 109.4% in 2023 and tumbled 1006.9% in 2025, its largest moves.
- Tracing EVO's Interest Expenses over 5 years: stood at $13.4 million in 2022, then plunged by 100.0% to $437.92 in 2023, then sank by 371.34% to -$1188.3 in 2024, then grew by 7.23% to -$1102.4 in 2025, then jumped by 89.27% to -$118.25 in 2026.
- Business Quant data shows EVO's Interest Expenses at -$118.25 in Q1 2026, -$1102.4 in Q3 2025, and -$3043.8 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | -118.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -118.25 |
| Mar 31, 2026 | -118.25 |
| Sep 30, 2025 | -1,102.42 |
| Sep 30, 2025 | -1,102.42 |
| Jun 30, 2025 | -3,043.84 |
| Jun 30, 2025 | -3,043.84 |
| Mar 31, 2025 | -1,058.20 |
| Mar 31, 2025 | -1,058.20 |
| Sep 30, 2024 | -1,188.27 |
| Sep 30, 2024 | -1,188.27 |
| Jun 30, 2024 | -4,059.87 |
| Jun 30, 2024 | -4,059.87 |
| Mar 31, 2024 | -95.60 |
| Mar 31, 2024 | -95.60 |
| Mar 31, 2023 | 437.92 |
| Mar 31, 2023 | 437.92 |
| Dec 31, 2022 | 13.43 Mn |
| Dec 31, 2022 | 13.43 Mn |
| Sep 30, 2022 | 3,080.28 |
| Sep 30, 2022 | 3,080.28 |